BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The company is eligible for 12 months exclusivity from launch
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
The centralized marketing authorization granted by the EC is valid in all EU Member
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure
Subscribe To Our Newsletter & Stay Updated
